 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 October 1996 | Volume 125 Issue 8 | Pages 658-668
Objectives: To review the virology, epidemiology, pathogenesis, natural history, clinical manifestations, and current treatment of hepatitis C virus (HCV) infection.
Data Sources: The MEDLINE database (1966 to 1996) was searched for English-language articles and abstracts on HCV and non-A, non-B hepatitis. Papers cited in relevant primary articles were also reviewed.
Study Selection: More than 500 original and review articles were evaluated, and the most relevant were selected.
Data Extraction: Data were extracted and reviewed by all authors.
Data Synthesis: In most patients, HCV infection results in chronic hepatitis. The disease is insidious and subclinical but may progress over decades into end-stage liver disease and hepatocellular carcinoma, which makes HCV cirrhosis a leading indication for orthotopic liver transplantation. Current diagnostic methods are highly sensitive and specific, and quantitative assessment of viral load may help to predict and monitor response to treatment. The only available therapeutic option is interferon, and this agent is effective in only a small subset of patients.
Conclusions: Infection with HCV is a significant public health problem that has important clinical and financial consequences. The tailoring of specific therapy according to viral load or genotype, better patient selection, and use of combination drug regimens may improve the chance of viral clearance and sustained biochemical and histologic response. Further understanding of the basic virology of HCV and the exact mechanisms of viral persistence and tissue injury is needed to help define future therapeutic and preventive strategies.
Ann Intem Med.1996; 125:658-668.
Author and Article Information
From Duke University Medical Center and Durham Veterans Administration Medical Center, Durham, North Carolina.
UPDATE
Hepatitis C
Requests for Reprints: Ala I. Sharara, MD, Box 3083, Duke University Medical Center, Durham, NC 27710.
Current Author Addresses: Dr. Sharara: Box 3083, Duke University Medical Center, Durham, NC 27710.
This article has been cited by other articles:
|
|
 |
|
  J. Vecchiet, K. Falasca, P. Cacciatore, P. Zingariello, M. Dalessandro, M. Marinopiccoli, E. D'Amico, C. Palazzi, C. Petrarca, P. Conti, et al. Association between Plasma Interleukin-18 Levels and Liver Injury in Chronic Hepatitis C Virus Infection and Non-Alcoholic Fatty Liver Disease Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 415 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Boston and J. C. Slish Management of HIV Infection in Persons Co-infected With Hepatitis Journal of Pharmacy Practice, August 1, 2005; 18(4): 295 - 309. [Abstract] [PDF]
|
|
|
|
|
|
J. D. Matthews and E. J. Bini Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C Journal of Pharmacy Practice, August 1, 2004; 17(4): 229 - 238. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Auffermann-Gretzinger, E. B. Keeffe, and S. Levy Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection Blood, May 15, 2001; 97(10): 3171 - 3176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Lamprecht, F Moosig, A Gause, K Herlyn, E Csernok, H Hansen, and W L Gross Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis Ann Rheum Dis, April 1, 2001; 60(4): 385 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Fischer, D. H. Tope, K. S. Conboy, B. D. Hedblom, E. Ronberg, D. K. Shewmake, and J. C. Butler Screening for Hepatitis C Virus in a Health Maintenance Organization Arch Intern Med, June 12, 2000; 160(11): 1665 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gale Jr., B. Kwieciszewski, M. Dossett, H. Nakao, and M. G. Katze Antiapoptotic and Oncogenic Potentials of Hepatitis C Virus Are Linked to Interferon Resistance by Viral Repression of the PKR Protein Kinase J. Virol., August 1, 1999; 73(8): 6506 - 6516. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Zhang, R. Hanecak, V. Brown-Driver, R. Azad, B. Conklin, M. C. Fox, and K. P. Anderson Antisense Oligonucleotide Inhibition of Hepatitis C Virus (HCV) Gene Expression in Livers of Mice Infected with an HCV-Vaccinia Virus Recombinant Antimicrob. Agents Chemother., February 1, 1999; 43(2): 347 - 353. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. A. Kalams and B. D. Walker The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses J. Exp. Med., December 21, 1998; 188(12): 2199 - 2204. [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Lee, J. D. Ji, J. E. Yeon, K. S. Byun, C. H. Lee, and G. G. Song Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection Ann Rheum Dis, December 1, 1998; 57(12): 728 - 731. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. K. H. Wong, D. D. Dudley, N. H. Afdhal, J. Dienstag, C. M. Rice, L. Wang, M. Houghton, B. D. Walker, and M. J. Koziel Liver-Derived CTL in Hepatitis C Virus Infection: Breadth and Specificity of Responses in a Cohort of Persons with Chronic Infection J. Immunol., February 1, 1998; 160(3): 1479 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Shaker, W. R. Reinus, and M. P. Whyte Hepatitis C-Associated Osteosclerosis: Late Onset after Blood Transfusion in an Elderly Woman J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 93 - 98. [Abstract] [Full Text]
|
|
|
|
|
|
A. I. Sharara, D. J. Perkins, M. A. Misukonis, S. U. Chan, J. A. Dominitz, and J. B. Weinberg Interferon (IFN)-alpha Activation of Human Blood Mononuclear Cells In Vitro and In Vivo for Nitric Oxide Synthase (NOS) Type 2 mRNA and Protein Expression: Possible Relationship of Induced NOS2 to the Anti-Hepatitis C Effects of IFN-alpha In Vivo J. Exp. Med., November 3, 1997; 186(9): 1495 - 1502. [Abstract] [Full Text] [PDF]
|
|
Article
